📊 MCRB Key Takeaways
Is Seres Therapeutics, Inc. (MCRB) a Good Investment?
Seres Therapeutics exhibits severe financial distress with minimal revenue of $358K, significant operating losses of $20.9M, and negative free cash flow of $16.4M annually, resulting in only ~1.8 years of cash runway. The company's 4.15x debt-to-equity ratio combined with $110M long-term debt creates elevated bankruptcy risk, with no clear path to profitability visible in current fundamentals.
Seres Therapeutics, Inc. Key Strengths (MCRB)
- Maintains positive cash balance of $29.8M providing near-term liquidity cushion
- Current ratio of 1.65x indicates ability to meet short-term obligations
- Active insider trading activity (9 Form 4 filings) suggests continued stakeholder engagement
MCRB Stock Risks: Seres Therapeutics, Inc. Investment Risks
- Extreme debt burden at 4.15x leverage with $110M long-term debt versus $26.5M equity
- Negative operating cash flow of $16.4M annually with limited runway at current burn rate
- Negligible revenue of $358K indicates failed commercialization or non-viable product pipeline
- Negative ROE (-75.1%) and ROA (-16.9%) demonstrate severe capital inefficiency
- Quick ratio of -1.09x signals potential liquidity crisis beyond current assets
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue trajectory and product pipeline advancement
- Debt refinancing requirements and covenant compliance
- Operating cash flow trend toward breakeven
- Insider transaction patterns indicating confidence or exits
Seres Therapeutics, Inc. (MCRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Seres Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MCRB Profit Margin, ROE & Profitability Analysis
MCRB vs Healthcare Sector: How Seres Therapeutics, Inc. Compares
How Seres Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Seres Therapeutics, Inc. Stock Overvalued? MCRB Valuation Analysis 2026
Based on fundamental analysis, Seres Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Seres Therapeutics, Inc. Balance Sheet: MCRB Debt, Cash & Liquidity
MCRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Seres Therapeutics, Inc.'s revenue has grown significantly by 348% over the 5-year period, indicating strong business expansion. The most recent EPS of $-17.77 indicates the company is currently unprofitable.
MCRB Revenue Growth, EPS Growth & YoY Performance
MCRB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $351.0K | $8.2M | $0.94 |
| Q3 2022 | $3.4M | -$15.6M | $-0.17 |
| Q2 2022 | $1.2M | -$35.5M | $-0.53 |
| Q1 2022 | $1.5M | -$35.5M | N/A |
| Q3 2021 | $80.0K | -$15.6M | $-0.17 |
| Q2 2021 | $5.2M | -$19.9M | N/A |
| Q1 2021 | $4.6M | -$19.9M | N/A |
| Q3 2020 | $80.0K | -$10.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Seres Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MCRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Seres Therapeutics, Inc. (CIK: 0001609809)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MCRB
What is the AI rating for MCRB?
Seres Therapeutics, Inc. (MCRB) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MCRB's key strengths?
Claude: Maintains positive cash balance of $29.8M providing near-term liquidity cushion. Current ratio of 1.65x indicates ability to meet short-term obligations.
What are the risks of investing in MCRB?
Claude: Extreme debt burden at 4.15x leverage with $110M long-term debt versus $26.5M equity. Negative operating cash flow of $16.4M annually with limited runway at current burn rate.
What is MCRB's revenue and growth?
Seres Therapeutics, Inc. reported revenue of $358.0K.
Does MCRB pay dividends?
Seres Therapeutics, Inc. does not currently pay dividends.
Where can I find MCRB SEC filings?
Official SEC filings for Seres Therapeutics, Inc. (CIK: 0001609809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MCRB's EPS?
Seres Therapeutics, Inc. has a diluted EPS of $-2.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MCRB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Seres Therapeutics, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MCRB stock overvalued or undervalued?
Valuation metrics for MCRB: ROE of -75.1% (sector avg: 15%), net margin of -5,562.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MCRB's AI grade for 2026?
Our dual AI analysis gives Seres Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MCRB's free cash flow?
Seres Therapeutics, Inc.'s operating cash flow is $-16.4M, with capital expenditures of $0.0. FCF margin is -4,569.8%.
How does MCRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,562.3% (avg: 12%), ROE -75.1% (avg: 15%), current ratio 1.65 (avg: 2).
Is Seres Therapeutics, Inc. carrying too much debt?
MCRB has a debt-to-equity ratio of 4.15x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.65 suggests adequate short-term liquidity.